Specialty Pharmacy

 

NEW YORK and SAN FRANCISCO — Pfizer on Monday announced that it would be acquiring biopharmaceutical company Medication in a cash deal valued at about $14 billion. The acquisition of Medivation, which is focused on developing and commercializing small molecules for oncology, I expected to have an immediately accretive impact on Pfizer’s adjusted diluted earnings per share upon closing, though Pfizer doesn’t anticipate it having an impact on its 2016 financial guidance. 

 

FLINT, Mich. — Specialty pharmacy provider and Diplomat company BioRx on Monday announced the release of the newest version of its iOS and Android app MyFactor. The app allows hemophilia patients to record bleeding episodes and treatment while facilitating easy information sharing with their caregivers, physicians, pharmacists and nurses. 

 

The new version provides cloud-based date storage and synchronization across multiple devices. 

 

TUKWILA, Wash. — Genoa on Thursday announced that it would be acquiring Advanced Care’s Behavioral Health and Residential Care Services Division, including 13 pharmacies in Michigan. The acquisition raises the number of Genoa pharmacies in Michigan to 24, with more than 325 nationally, most of which are located onsite at community mental health centers.

 

GREENVILLE, N.C. — Mayne Pharma on Thursday announced that it had acquired a portfolio of dermatology foam products from GSK in $50.1 million deal. Among the portfolio’s products are U.S. rights to acne treatment Fabior (tazarotene) foam and plaque psoriasis treatment Sorilux (calcipotriene) foam. The company also gains the Canadian rights to Luxiq and Olux-E, as well as Mexican rights to betamethasone foam. 

 

CHESTERFIELD, U.K. — Mallinckrodt announced Thursday that it would be building a new campus for its specialty brands organization in Bedminster, N.J.’s Somerset Financial Center. The company will invest more than $80 million in New Jersey, and expects that some 400 employees will occupy the new space in the first quarter of 2017. The new location will consolidate the operations for its specialty brands groups.

 

FLINT, Mich. — Diplomat Pharmacy announced Monday that it is now filling prescriptions for the recently approved Zinbryta (daclizumab), a drug to treat relapsing forms of multiple sclerosis. The drug is generally reserved for patients with inadequate responses to two or more MS therapies. 

 

“A relapse of any kind can cause a person to lose hope,” Diplomat president Gary Kadlec said. “For people with relapsing multiple sclerosis, Zinbryta has the potential to restore that hope and make life a little easier.”

FLINT, Mich. — Diplomat Pharmacy on Tuesday announced the results of its second quarter, reporting total revenue of $1.09 billion, a 35% increase over the same quarter in 2015.